Alternative mechanisms of action have since gained traction in MASH treatment. Madrigal Pharmaceuticals’s Rezdiffra (resmetirom), a small molecule THRB agonist, was the first drug approved by the FDA ...

Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a phase 1 candidate for metabolic-associated steatohepatitis (MASH) and other ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

A case study on how DelveInsight helped a pharma client navigate the evolving metabolic dysfunction-associated steatohepatitis (MASH) landsca ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Eli Lilly (NYSE:LLY) recently announced its plans to invest $27 billion in four new U.S. manufacturing plants over the next five years, creating thousands of jobs. This move comes at a time when ...

Eli Lilly (LLY) has agreed to acquire Organovo Holdings ... has shown a significant reduction in liver fat in a Phase II study on MASH (metabolic dysfunction-associated steatohepatitis ...

Eli Lilly (NYSE: LLY) stock defied today's market ... colitis and metabolic dysfunction-associated steatohepatitis (MASH). Where to invest $1,000 right now? Our analyst team just revealed what ...